title: Management of Stage IIIA (N2) Non-Small Cell Lung Cancer.
abstract: There is no consensus as to the optimal management of IIIA (N2) non-small cell lung cancer, nor for the role of surgery in treating this disease stage. Clinical trial evidence struggles to keep up with technology advancement and the evolution of expert opinion. Despite advances in chemotherapeutic regimens, methods of delivery for radiation, and less invasive surgical techniques, survival for patients with stage IIIA-N2 malignancies remains poor. Further developments in both will stimulate and maintain controversy in the field for years to come.
authors.affiliation: Division of Thoracic Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA.
authors.forename: Erin A
authors.initials: EA
authors.lastname: Gillaspie
authors.affiliation: Division of Thoracic Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. Electronic address: wigle.dennis@mayo.edu.
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Wigle
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D019468:Disease Management; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging
keywords: Adjuvant; N2; Neoadjuvant; Non–small cell lung cancer; PORT; Stage IIIA; Surgery